News and Press Releases
Press releases
Theralase® Announces Leadership Reorganization
Toronto, Ontario – November 15, 2021, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinic...
0Theralase® Releases Q221 Unaudited Financial Statements and Quarterly Newsletter
Toronto, Ontario – August 30, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), A clinical s...
0Theralase® Announces Leadership Transition
Toronto, Ontario – August 19, 2021, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical...
0Theralase Launches Seventh US-Based Clinical Study Site and Treats First Patient in the US
Toronto, Ontario – June 11, 2021, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical s...
0Theralase Release Q12021 Interim Financial Statements
Toronto, Ontario – May 28, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stag...
0Theralase Release FY2020 Audited Financial Statements
Toronto, Ontario – April 28, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical s...
0Theralase Releases Quarterly Newsletter
Toronto, Ontario – April 27, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical st...
0Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine
Toronto, Ontario – April 9, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical sta...
0Theralase launches Anti-Cancer Therapy Research Centre
Toronto, Ontario – March 29, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical s...
0Theralase Launches Sixth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
Toronto, Ontario – March 25, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical s...
0in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.